Market Analysis & Reporting
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Market Analysis & Reporting
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Market Analysis & Reporting
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
9.90
-0.16 (-1.59%)
Latest market quote · 2026-08-07 20:00 (UTC)
Company profile
Healthcare
Biotechnology
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Company websiteIssued common shares
Shares available to trade
Price relative to trailing earnings
Price relative to forecast earnings
Sensitivity relative to the market
Mean published price target
Reported full-time workforce
Shares held by institutions
Current session activity
High-to-low move
Share of advancing days
Based on daily returns
Versus provisional U.S. equity benchmark
Annualized negative-return risk
Historical one-day loss threshold
Reader research
Join the discussion
Log in to share sentiment, a price target, and your investment thesis.
Log in to commentShares held by company insiders
Largest one-day advance
Largest one-day decline
Largest one-year decline
Low-to-high range position
Shares sold short
Percent of public float
Short-interest ratio
Nearest-expiry open interest
Price, momentum, breadth and range
Scores are technical indicators derived from the available one-year price history and are not investment recommendations. Short-interest and options figures display when supplied by the market-data provider.